Orbimed Advisors LLC Mereo Biopharma Group PLC Transaction History

Orbimed Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.71 - $1.22 $2.03 Million - $3.49 Million	-2,857,631 Reduced 26.94%	7,747,891 $5.5 Million
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $733,162 - $1.55 Million	894,100 Added 9.21%	10,605,522 $9.13 Million
Q2 2022 Aug 15, 2022	SELL	$0.33 - $1.69 $2.49 Million - $12.8 Million	-7,553,342 Reduced 43.75%	9,711,422 $10.9 Million
Q2 2021 Aug 16, 2021	BUY	$2.94 - $4.08 $2 - $4	1 Added 0.0%	17,264,764 $54.7 Million
Q1 2021 May 17, 2021	BUY	$2.6 - $4.43 $8.97 Million - $15.3 Million	3,448,275 Added 24.96%	17,264,763 $58.2 Million
Q4 2020 Feb 16, 2021	BUY	$1.95 - $3.6 $26.9 Million - $49.7 Million	13,816,488 New	13,816,488 $49.5 Million

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $376M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.